Click here to close now.

SYS-CON MEDIA Authors: VictorOps Blog, Tim Hinds, Mike Kavis, Peter Silva, Glenn Rossman

News Feed Item

MYOS Corporation Reports 2014 Second Quarter Results

MYOS Management to Host Corporate Overview Conference Call Today at 11:00 AM ET

CEDAR KNOLLS, NJ -- (Marketwired) -- 08/14/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today its financial results for the second quarter ended June 30, 2014. The Company also provided highlights of its recent progress and anticipated near-term research and development milestones for Fortetropin™, the first clinically proven natural myostatin inhibitor.

SECOND QUARTER AND RECENT HIGHLIGHTS

  • Reported positive top-line clinical data demonstrating that Fortetropin significantly increases muscle size and lean body mass in average males with modest resistance training;
  • Received listing approval and began trading on the NASDAQ Capital Market;
  • Appointed world-renowned scientific visionary and entrepreneur, J. Craig Venter to the Board of Directors;
  • Announced a small molecule development program with Cloud Pharmaceuticals, Inc. focused on Furin convertase regulation and Janus Kinase 3 inhibition as targets for small molecule candidates and their activity in muscle and inflammation;
  • Appointed seasoned pharmaceutical finance and accounting industry veteran, Joseph C. DosSantos, as Chief Financial Officer;
  • Established a multi-year science research collaboration with the Rutgers University Musculoskeletal Tissue Regeneration Laboratory and became a corporate sponsor of Rutgers Athletics;
  • Received a Notice of Allowance from the U.S. Patent and Trademark Office for the patent covering proprietary methods of manufacturing Fortetropin which will protect the Company's intellectual property portfolio though 2033;
  • Extended the Fortetropin manufacturing and supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V, the German Institute for Food Technologies, through the end of 2016; and
  • Appointed consumer product industry veteran Douglas Weekes as Chief Commercial Officer to lead the Company's marketing, sales and product development of a portfolio of commercial products derived from Fortetropin.

"The last several months have represented a remarkable and transformational time in the early history of MYOS. After building a strong business foundation, MYOS has delivered on a number of important milestones central to our long term goal of growing into a leader in the field of muscle health. Towards that end, MYOS has built the financial and operating infrastructure required to become a NASDAQ-listed company and we are thrilled to have attracted one of the most important scientific minds of the last century to our board of directors. MYOS has made substantial progress on both the bionutrition and biotherapeutics front witnessed by recent strategic collaborations and the completion of our second clinical study," commented Robert J. Hariri, M.D., Ph.D., Chairman of the Board of MYOS.

"The positive clinical results from our Tampa study provide confirmatory data that Fortetropin can significantly build and support growth and retention of healthy muscle and improve lean body mass in modestly-trained individuals participating in a recreational resistance exercise program. Armed with this important clinical data, MYOS firmly believes that the use of Fortetropin along with exercise has broad applications in a wide range of indications. Furthermore, the data suggests that Fortetropin may also serve to address the unmet need for a safe and effective treatment for sarcopenia as well as in the management of muscle wasting seen in cachexia or chronic illness. MYOS expects further strategic momentum in the second half of 2014 and throughout 2015 due to several anticipated key milestones including the development and launch of new products to build out the bionutrition business, and additional clinical and preclinical study results," Dr. Hariri concluded.

EXPECTED NEAR-TERM MILESTONES

  • Full clinical data from University of Tampa study on use of Fortetropin in modestly-trained males to be presented at a scientific congress;
  • Results from the Fortetropin study in adult women expected in 2015;
  • Formulation of meal replacement beverage and nutritional protein bars utilizing Fortetropin targeted for end of 2014;
  • Completion of the Rutgers University Musculoskeletal Tissue Regeneration Laboratory project developing cell-based assays for high throughput screening studies of next generation myostatin inhibitors on target for mid-2015; and
  • Report on the Cloud Pharmaceuticals, Inc. identification of initial small molecule Furin convertase inhibitors in the myostatin regulatory pathway by the end of 2015.

CONFERENCE CALL AND WEBCAST INSTRUCTIONS
MYOS's management team will host a conference call and webcast for interested parties to discuss the financial results and provide a business update on Thursday, August 14, 2014 at 11:00 a.m. ET. Interested participants may access this conference call by dialing 877-407-7186 (U.S./Canada) or 201-689-8052 (International).

The webcast may be accessed via the News and Events page of the Investor Relations section of the MYOS corporate web site at www.myoscorp.com, and will be archived for 30 days. Webcast participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

SECOND QUARTER 2014 FINANCIAL SUMMARY

For the second quarter of 2014, the Company's net sales were approximately $1,679 thousand compared to net sales of approximately $715 thousand for the second quarter of 2013 and approximately $1,546 thousand for the first quarter of 2014. Net sales for the trailing twelve months were approximately $5,551 thousand.

Loss from operations was approximately ($1,001) thousand for the second quarter of 2014 compared to approximately ($985) thousand for the second quarter of 2013 and approximately ($423) thousand for the first quarter of 2014. Loss from operations includes the Company's investment in research and development activities in the second quarter of 2014 of approximately $295 thousand compared to approximately $107 thousand in the second quarter of 2013 and approximately $434 thousand in the first quarter of 2014.

Net loss for the second quarter of 2014 was approximately ($1,000) thousand compared to approximately ($984) thousand for the second quarter of 2013 and approximately ($422) thousand for the first quarter of 2014. Basic and diluted net loss per share was $(0.34) for the second quarter of 2014 compared to $(0.44) for the second quarter of 2013 and $(0.16) for the first quarter of 2014. Per share results are based on weighted average number of shares outstanding of 2.909 million for the second quarter of 2014 compared to 2.212 million for the second quarter of 2013 and 2.703 million for the first quarter of 2014.

Non-GAAP, net loss for the second quarter of 2014 was approximately ($523) thousand compared to approximately ($608) thousand for the second quarter of 2013 and approximately ($119) for the first quarter of 2014. Non-GAAP basic and diluted net loss per share was ($0.18) for the second quarter of 2014 compared to ($0.27) for the second quarter of 2013 and ($0.04) for the first quarter of 2014. Non-GAAP net loss excludes stock-based compensation of approximately $422 thousand, amortization expense of approximately $50 thousand and impairment charges of approximately $5 thousand for the second quarter of 2014 compared to stock-based compensation of approximately $365 thousand and changes in fair value of warrants of approximately $11 thousand for the second quarter of 2013 and stock-based compensation of approximately $303 thousand for the first quarter of 2014.

The Company had cash of approximately $2,296 thousand and total assets of approximately $8,335 thousand as of June 30, 2014 compared to cash of approximately $451 thousand and total assets of approximately $3,836 thousand as of December 31, 2013.

In addition to the GAAP financial measures set forth in this press release, the Company has included non-GAAP net loss and non-GAAP basic and diluted net loss per share measures, which present results on a basis adjusted for certain items. Non-GAAP net loss and non-GAAP basic and diluted net loss per share are supplemental measures of performance that are not required by, or presented in accordance with, GAAP. The Company uses these non-GAAP measures as key performance measures for the purpose of evaluating performance internally. The Company also believes these non-GAAP measures provide the Company's investors with useful information regarding the Company's historical operating results. These non-GAAP measures are not intended to replace the presentation of the Company's financial results in accordance with GAAP. Use of the terms non-GAAP net loss, and non-GAAP basic and diluted net loss per share may differ from similar measures reported by other companies. We define non-GAAP net loss as net loss adjusted for stock-based compensation and certain special charges that are otherwise included in GAAP net loss, including changes in fair value of warrants, amortization and impairment charges. Non-GAAP basic and diluted net loss per share refers to non-GAAP net loss divided by the weighted average number of basic and diluted shares outstanding. All of the non-GAAP measures discussed above are reconciled from their respective GAAP measures in the "Reconciliation of GAAP to Non-GAAP Net Loss" table set forth below.

A summary of key financial highlights for the three and six months ended June 30, 2014 and 2013 is as follows:


                      MYOS CORPORATION AND SUBSIDIARY
        CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
            (Unaudited; in thousands, except per share amounts)

                                     Three Months Ended   Six Months Ended
                                          June 30,            June 30,
                                       2014      2013      2014      2013
                                     --------  --------  --------  --------
Net sales                            $  1,679  $    715  $  3,225  $    993
Cost of sales (excludes amortization
 of acquired intangibles)                 645       318     1,050       445
                                     --------  --------  --------  --------
  Gross profit                          1,034       397     2,175       548

Research and development                  295       107       729       285
Selling, general and administrative     1,685     1,275     2,815     2,340
Amortization                               50         -        50         -
Loss on asset impairments                   5         -         5         -
                                     --------  --------  --------  --------
  Total operating expenses              2,035     1,382     3,599     2,625

      Operating loss                   (1,001)     (985)   (1,424)   (2,077)

  Other income (expense):
    Interest income                         1         1         2         3
                                     --------  --------  --------  --------
      Total other income (expense)          1         1         2         3
                                     --------  --------  --------  --------

Net loss and comprehensive loss        (1,000)     (984)   (1,422)   (2,074)
                                     ========  ========  ========  ========

Basic and diluted net loss per share
 attributable to common stockholders $  (0.34) $  (0.44) $  (0.51) $  (0.94)
                                     ========  ========  ========  ========

Weighted average number of common
 shares outstanding, basic and
 diluted                                2,909     2,212     2,807     2,208
                                     ========  ========  ========  ========



                      MYOS CORPORATION AND SUBSIDIARY
                        CONSOLIDATED BALANCE SHEETS
                  (in thousands, except per share amounts)

                                                  June 30,     December 31,
                                                    2014           2013
                                               -------------  -------------
                                                (Unaudited)
ASSETS
Current assets
Cash                                           $       2,296  $         451
Accounts receivable                                    2,333            645
Inventories                                            1,169            143
Prepaid expenses and other current assets                214            215
                                               -------------  -------------
Total current assets                                   6,012          1,454
Fixed assets, net of accumulated depreciation            331            344
Intangible assets, net of accumulated
 amortization                                          1,992          2,038
                                               -------------  -------------
Total assets                                   $       8,335  $       3,836
                                               =============  =============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable                               $         617  $         184
Accrued expenses                                         482            312
                                               -------------  -------------
Total current liabilities                              1,099            496
                                               -------------  -------------

Total liabilities                                      1,099            496
                                               -------------  -------------

Commitments and contingencies

Stockholders' equity
Preferred stock, $.001 par value; 500,000
 shares authorized; no shares issued and
 outstanding                                               -              -
Common stock, $.001 par value, 6,000,000
 shares authorized; 2,909,285 and 2,227,447
 shares issued and outstanding at June 30,
 2014 and December 31, 2013, respectively                  3              2
Additional paid-in capital                            22,563         17,246
Accumulated deficit                                  (15,330)       (13,908)
                                               -------------  -------------
Total stockholders' equity                             7,236          3,340
                                               -------------  -------------

Total liabilities and stockholders' equity     $       8,335  $       3,836
                                               =============  =============



                      MYOS CORPORATION AND SUBSIDIARY
                Reconciliation of GAAP to Non-GAAP Net Loss
            (Unaudited; in thousands, except per share amounts)


                                     Three Months Ended   Six Months Ended
                                          June 30,            June 30,
                                       2014      2013      2014      2013
                                     --------  --------  --------  --------
GAAP - net loss                        (1,000)     (984)   (1,422)   (2,074)

Stock-based compensation                  422       365       725       719
Change in fair value of warrants            -        11         -        19
Amortization                               50         -        50         -
Impairment charges                          5         -         5         -

                                     --------  --------  --------  --------
Non-GAAP - net loss                      (523)     (608)     (642)   (1,336)
                                     --------  --------  --------  --------

Weighted average number of common
 shares outstanding, basic and
 diluted                                2,909     2,212     2,807     2,208

GAAP basic and diluted net loss per
 share                               $  (0.34) $  (0.44) $  (0.51) $  (0.94)

Non-GAAP basic and diluted net loss
 per share                           $  (0.18) $  (0.27) $  (0.23) $  (0.61)

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products including new products described herein, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights and the issuance of the patent described herein, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

MYOS Corporation Investor and Media Contact:

Jenene Thomas
Investor Relations and Corporate Communications
(973) 509-0444
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
One of the biggest impacts of the Internet of Things is and will continue to be on data; specifically data volume, management and usage. Companies are scrambling to adapt to this new and unpredictable data reality with legacy infrastructure that cannot handle the speed and volume of data. In his session at @ThingsExpo, Don DeLoach, CEO and president of Infobright, will discuss how companies need to rethink their data infrastructure to participate in the IoT, including: Data storage: Understand...
Since 2008 and for the first time in history, more than half of humans live in urban areas, urging cities to become “smart.” Today, cities can leverage the wide availability of smartphones combined with new technologies such as Beacons or NFC to connect their urban furniture and environment to create citizen-first services that improve transportation, way-finding and information delivery. In her session at @ThingsExpo, Laetitia Gazel-Anthoine, CEO of Connecthings, will focus on successful use c...
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, includin...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of present...
VictorOps is making on-call suck less with the only collaborative alert management platform on the market. With easy on-call scheduling management, a real-time incident timeline that gives you contextual relevance around your alerts and powerful reporting features that make post-mortems more effective, VictorOps helps your IT/DevOps team solve problems faster.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, will discuss why containers should be paired with new architectural practices such as microservices ra...
Roberto Medrano, Executive Vice President at SOA Software, had reached 30,000 page views on his home page - http://RobertoMedrano.SYS-CON.com/ - on the SYS-CON family of online magazines, which includes Cloud Computing Journal, Internet of Things Journal, Big Data Journal, and SOA World Magazine. He is a recognized executive in the information technology fields of SOA, internet security, governance, and compliance. He has extensive experience with both start-ups and large companies, having been ...
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focu...
Operational Hadoop and the Lambda Architecture for Streaming Data Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes ...
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, it is now feasible to create a rich desktop and tuned mobile experience with a single codebase, without compromising performance or usability.
SYS-CON Events announced today Arista Networks will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Arista Networks was founded to deliver software-driven cloud networking solutions for large data center and computing environments. Arista’s award-winning 10/40/100GbE switches redefine scalability, robustness, and price-performance, with over 3,000 customers and more than three million cloud networking ports depl...
Application metrics, logs, and business KPIs are a goldmine. It’s easy to get started with the ELK stack (Elasticsearch, Logstash and Kibana) – you can see lots of people coming up with impressive dashboards, in less than a day, with no previous experience. Going from proof-of-concept to production tends to be a bit more difficult, unfortunately, and it tends to gobble up our attention, time, and money. In his session at DevOps Summit, Otis Gospodnetić, co-author of Lucene in Action and founder...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, will explain the best practices of continuous testing at high scale, which is r...